New study finds higher percentage of body fat is associated more with abnormal blood glucose in normal and overweight nondiabetic subjects.
The new diabetes tech in question is the expanding pool of continuous glucose monitoring systems. So, what's your CGM IQ?
New research also found that continuous glucose monitoring by type 1 diabetes patients improved overall glucose control and enhanced quality of life.
New diabetes studies find SGLT2i may reduce all-cause mortality; that telemedicine can improve T2DM care; and that broader screening criteria are better.
Primary hyperparathyroidism--asymptomatic but curable. Here are three clinical pearls to help guide diagnosis and management.
The GLP-1 receptor agonist/metformin combination did not support weight loss in this population but did increase pregnancy rates per in vitro embryo transfer.
Empagliflozin shown to significantly reduce liver fat in patients with T2DM, according to a new study.
In a new study, the GLP-1 receptor agonist semaglutide was associated with greater weight loss than placebo -- and liraglutide.
A high-energy breakfast diet may be an effective strategy to improve diabetes control, according to a new study.
Three new diabetic technologies have been approved by the FDA. What are they? Scroll through our slideshow to find out.